DDInter233 DDInter1658
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Brigatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ubrogepant
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Levonorgestrel
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Brigatinib may lead to a major life threatening interaction when taken with Levonorgestrel
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib